GNGabriel-Stefan Nadj

Gabriel-Stefan Nadj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabriel-Stefan Nadj has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cybersecurity in clinical practice

    by Daniel Bjelica, Gabriel-Stefan Nadj, Artur Bjelica

    Introduction. The digitalisation of healthcare systems has led to a rapid proliferation of cybersecurity threats that directly affect everyday clinical practice. Electronic health records, networked medical devices, and telemedicine platforms have become integral to modern medicine while simultaneously representing potential attack surfaces. Clinicians make daily decisions with data security implications, and inadequate training leaves them particularly vulnerable. Threats and vulnerabilities. Ransomware attacks that paralyse hospital systems, phishing campaigns targeting clinical staff, attacks on medical Internet of Things devices, and software supply chain compromise are the most prevalent threats in the contemporary healthcare environment. Each carries direct consequences for patient safety and continuity of care. Clinician roles and advanced technologies. Clinical staff represent both the most frequent point of system compromise and the most important line of defence. Advanced technologies including artificial intelligence based threat detection, blockchain data integrity, and federated learning offer emerging solutions, but require strategic institutional commitment for successful deployment. Conclusion. Cybersecurity is not exclusively an information technology matter - it is an integral component of medical ethics and responsibility towards patients. Its routine integration into clinical practice requires education, clear institutional procedures, and adequate resources.

  • Multifocal caesarean scar endometriosis with extensive abdominal wall involvement: A case report

    by Bojana Jovancevic, Aleksandra Vejnovic, Gabriel-Stefan Nadj, Aleksandra Ilic

    Introduction. Caesarean scar endometriosis is a rare form of abdominal wall endometriosis that develops following caesarean delivery as a result of ectopic implantation of endometrial tissue within the surgical scar. Patients typically present with cyclic pain and a palpable abdominal wall mass, although diagnosis may be challenging because it resembles other abdominal wall lesions. Case Report. A 31-year-old woman presented with painful nodules located within a previous Cohen laparotomy scar. Symptoms began approximately one year after caesarean delivery and were strongly associated with menstruation. Ultrasonography demonstrated multiple heterogeneous lesions within the scar. Surgical exploration revealed multifocal endometriosis involving the skin, subcutaneous tissue and fascia. Complete excision of all visible lesions was performed. Histopathological examination confirmed abdominal wall endometriosis by demonstrating endometrial glands and stroma associated with haemorrhage, haemosiderin-laden macrophages, and fibrosis. The postoperative course was uneventful, and satisfactory wound healing was observed at the two-week follow-up visit. Conclusion. This case illustrates an uncommon presentation of caesarean scar endometriosis characterised by multifocal disease and extensive abdominal wall involvement. Caesarean scar endometriosis should be considered in women with cyclic pain and a mass arising within a previous caesarean section scar. Early recognition and complete surgical excision remain essential for definitive diagnosis and effective treatment.

  • Artificial intelligence in in vitro fertilization: Current applications, limitations and future directions

    by Daniel Bjelica, Tijana Stanivukovic, Gabriel-Stefan Nadj, David Strilic, Artur Bjelica

    Introduction. Infertility represents a major global health challenge with profound medical, psychological, and social consequences. Despite substantial advances in assisted reproductive techniques, the success rates of in vitro fertilization remain limited, largely due to subjectivity in embryo selection and variability in ovarian stimulation management. Application of artificial intelligence in embryo selection. Artificial intelligence systems enable the analysis of large and complex datasets, including morphological and morphokinetic embryo characteristics derived from static imaging and continuous developmental monitoring. These approaches enhance the standardization of embryo quality assessment and reduce interobserver variability; however, their performance remains constrained by the quality of training data and the incomplete representation of biological determinants of implantation. Role of artificial intelligence in ovarian stimulation management. Algorithms integrating clinical, hormonal, and ultrasonographic parameters facilitate individualized gonadotropin dosing, more accurate determination of final oocyte maturation timing, and reduction of ovarian hyperstimulation risk. Existing studies demonstrate a high level of concordance between algorithm-based recommendations and expert clinical decision-making. Future directions. Further advancements are anticipated through the development of multimodal models integrating morphological, clinical, and genetic data, alongside the implementation of explainable systems to enhance transparency and clinical trust. Conclusion. Currently, artificial intelligence serves primarily as a decision-support tool rather than a substitute for clinical expertise. Its routine clinical implementation requires robust prospective validation and regulatory approval.

  • Open Access

    Vulvar malignant melanoma - case report

    by Marko Stojic, Milos Pantelic, Jovan Ugarkovic, Gabriel-Stefan Nadj, Aleksandra Ilic

    Introduction. Vulvar carcinoma is a rare gynecological malignancy, accounting for 0.6 percent of all female cancers. Case Report. A-76-year-old woman presented with a tumorous lesion in the lower third of the left labia majora and minora, measuring approximately 25 mm. A multifocal biopsy was conducted, and pelvic magnetic resonance imaging revealed slight enlargement of a left inguinal solid lymph node. The patient underwent a left hemivulvectomy with inguinofemoral lymphadenectomy. Histopathological analysis confirmed a malignant lentiginous tumor, and inguinofemoral lymphadenectomy revealed metastatic malignant melanoma. Despite a negative histopathological finding of the contralateral side during the initial biopsy, the patient returned within three months with a 9-mm mucosal nodular type melanoma on the lower third of the right labia majora. A wide excision of the vulva was subsequently performed. Following consultation with a multidisciplinary tumor board, adjuvant immunotherapy with Pembrolizumab (200 mg per cycle, 9 cycles) was initiated. Conclusion. Vulvar malignant melanoma is rare, aggressive, and unpredictable tumor that predominantly affects women in later life. It is associated with a high recurrence rate and a poor overall prognosis.


  • Open Access

    Survival analysis of patients with rare tumors of the uterine corpus – carcinosarcoma

    by Nemanja Stevanovic, Aljosa Mandic, Slobodan Maricic, Gabriel Stefan Nadj, Tamara Maksimovic, Nevena Stanulovic, Vladimir Cancar, Milan Rodic

    Background/Aim. Uterine carcinosarcoma (UCS), formerly known as malignant mixed M?llerian tumor, is a rare, aggressive malignancy of the female genital tract. The aim of this study was to analyze the most important clinical and pathohistological characteristics of UCSs on operated patients, as well as to determine which of those factors are affecting progression-free survival (PFS) and overall survival (OS) of patients. Methods. The study was conducted as a retrospective analysis of medical data documentation of patients with a diagnosis of UCS who were surgically treated at the Department of Gynecology, Clinic for Operative Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia, in 10 years? period (from the beginning of 2009 to the end of 2018). The analysis included data for a total of 31 patients. Results. Of all the examined parameters (age of the patient, clinical stage of the disease, histological grade, depth of myometrial invasion, and lymphovascular invasion ? LVI), the greatest influence on the choice of therapeutic procedure had a histological tumor grade. Conclusion. Our research showed the joint influence of the examined clinical and pathohistological factors on PFS and OS of patients with UCS. The only independent parameter that showed a statistically significant impact on survival is LVI.

  • Top Cited Papers

    Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

    by Tobias V. Lanz, R. Camille Brewer, Peggy P. Ho, Jae-Seung Moon, Kevin M. Jude, Daniel Fernandez, Ricardo A. Fernandes, Alejandro M. Gomez, Gabriel-Stefan Nadj, Christopher M. Bartley, et al.

    Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system. B lymphocytes in the cerebrospinal fluid (CSF) of patients with MS contribute to inflammation and secrete oligoclonal immunoglobulins1,2. Epstein–Barr virus (EBV) infection has been epidemiologically linked to MS, but its pathological role remains unclear3. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM) and provide structural and in vivo functional evidence for its relevance. A cross-reactive CSF-derived antibody was initially identified by single-cell sequencing of the paired-chain B cell repertoire of MS blood and CSF, followed by protein microarray-based testing of recombinantly expressed CSF-derived antibodies against MS-associated viruses. Sequence analysis, affinity measurements and the crystal structure of the EBNA1–peptide epitope in complex with the autoreactive Fab fragment enabled tracking of the development of the naive EBNA1-restricted antibody to a mature EBNA1–GlialCAM cross-reactive antibody. Molecular mimicry is facilitated by a post-translational modification of GlialCAM. EBNA1 immunization exacerbates disease in a mouse model of MS, and anti-EBNA1 and anti-GlialCAM antibodies are prevalent in patients with MS. Our results provide a mechanistic link for the association between MS and EBV and could guide the development of new MS therapies.


  • Open Access

    Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM

    by Tobias V Lanz, R Camille Brewer, Peggy P Ho, Kevin M Jude, Daniel Fernandez, Jae-Seung Moon, Ricardo A Fernandes, Alejandro M Gomez, Gabriel-Stefan Nadj, Christopher M Bartley, et al.

    Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system (CNS). B lymphocytes in the cerebrospinal fluid (CSF) of MS patients contribute to inflammation and secrete oligoclonal immunoglobulins. Epstein-Barr virus (EBV) infection has been linked to MS epidemiologically, but its pathological role remains unclear. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBNA1 and the CNS protein GlialCAM, and provide structural and in-vivo functional evidence for its relevance. A cross-reactive CSF-derived antibody was initially identified by single-cell sequencing of the paired-chain B cell repertoire of MS blood and CSF, followed by protein microarray-based testing of recombinantly expressed CSF-derived antibodies against MS-associated viruses. Sequence analysis, affinity measurements, and the crystal structure of the EBNA1-peptide epitope in complex with the autoreactive Fab fragment allowed for tracking the development of the naïve EBNA1-restricted antibody to a mature EBNA1/GlialCAM cross-reactive antibody. Molecular mimicry is facilitated by a post-translational modification of GlialCAM. EBNA1 immunization exacerbates the mouse model of MS and anti-EBNA1/GlialCAM antibodies are prevalent in MS patients. Our results provide a mechanistic link for the association between MS and EBV, and could guide the development of novel MS therapies.